Solanezumab Completed Phase 3 Trials for Alzheimer's Disease (AD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00904683Effect of LY2062430 on the Progression of Alzheimer's Disease
NCT00905372Effect of LY2062430 on the Progression of Alzheimer's Disease